p53 and p21WAF1/CiP1 in Colorectal Carcinoma
Author Information
Author(s): RJC Slebos, 10 Baas, M Clement, M Polak, J-W Mulder, FM van den Berg, SR Hamilton, GJA Offerhaus
Primary Institution: Academic Medical Centre, University of Amsterdam; The Johns Hopkins University School of Medicine
Hypothesis
Does the inactivation of the p53 tumor-suppressor gene correlate with the expression of p21WAF1/CiP1 in colorectal carcinoma?
Conclusion
Inactivation of p53 and altered expression of p21WAF1/CiP1 are common in colorectal carcinoma but do not correlate with each other or with clinical or pathological parameters.
Supporting Evidence
- 41% of the tumors had p53 mutations.
- 46% of the tumors showed positive immunohistochemistry for p53.
- 38% of cases had positive p21WAF1/CiP1 staining.
- Mutations in p53 correlated with loss of heterozygosity at 17p.
Takeaway
This study looked at how a gene called p53, which helps prevent cancer, is affected in colorectal cancer, and found that changes in this gene don't always relate to another protein called p21.
Methodology
The study analyzed 46 colorectal carcinoma samples for p53 mutations using immunohistochemistry and DNA sequencing, and assessed p21WAF1/CiP1 expression.
Limitations
The study group was relatively small, which may limit the generalizability of the findings.
Participant Demographics
24 men and 22 women, aged 49 to 83 years.
Statistical Information
P-Value
0.027
Statistical Significance
p=0.027
Want to read the original?
Access the complete publication on the publisher's website